Kornimate/medical-research-clean huggingface dataset:
longitudinal study of asthma from birth to adulthood

Conditions: Asthma; Lung Diseases

Summary: to extend follow-up of a birth cohort of asthmatic children through adolescence and on to adulthood. .

background: the population under study is the cohort from tucson children's respiratory study (crs), which began in 1980. design narrative: the longitudinal study follows a birth cohort of children, initially established in the 1980s. the study period took the children through their 16th birthday, when a comprehensive respiratory and allergy assessment was conducted. this extended follow-up took the cohort from birth to an age at which lung growth is virtually complete for girls and ending its most rapid phase for boys. the resulting data set was used to test diverse hypotheses concerned with lower respiratory tract illnesses (lri), asthma, wheezing, allergy, and smoking. there were four broad areas: 1) effects of lri during the first three years of life and early and late symptoms and allergic sensitization on the picture of asthma; 2) changes during adolescence in symptoms and airways responsiveness; 3) the natural history of allergic sensitization and its relation to asthma and asthma-like symptoms; and 4) the change in longitudinal lung function and factors affecting the change. a well documented data set was available to test these hypotheses. lri were documented during the first three years of life, atopy was evaluated, symptom status tracked, and lung function periodically measured. infant lung function was assessed for a sample of the children and methacholine challenge was performed at age 11. in the evaluation at age 16 years, symptoms, lung function, including methacholine responsiveness, and atopy and lymphocyte phenotype were assessed. various methods for longitudinal data analysis were used. the study was renewed in 2001 to follow the birth cohort into early adulthood in order to generate data on the mechanisms and risk factors associated with asthma in early adult life. specifically the study will: 1) identify factors that alter persistence and remission of asthma symptoms among young adults who developed asthma in childhood; 2) assess the role of persistent eosinophilia during childhood as a mechanism which determines progression and incidence of asthma in early adult life, and prevalence of persistent bronchial hyperresponsiveness (bhr); 3) measure noninvasive markers of airway inflammation in early adult life, and identify correlates of these markers, both with childhood and current asthma symptoms, bhr and immune system indicators of allergy; 4) predict early (by age 20 ) decline in lung function with reference to childhood lower respiratory tract illnesses, asthma-like symptoms, and the initiation of smoking; and 5) investigate the role of gender in incidence of and risk factors for asthma during adolescence and young adult life.

Eligibility criteria:
no eligibility criteria
effect and prognosis of immunohistochemical biomarkers changes in patients with bladder cancer after neoadjuvant chemotherapy

Conditions: Bladder Cancer

Summary: clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers gata-3, ck20, p53 and ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.

this is a retrospective study included bladder cancer patients treated with neoadjuvant chemotherapy. we analyzed the changes in the expression of gata-3, ck20, p53 and ki67 before and after nac. evaluating the sensitivity factor for predicting pathological complete response.

Eligibility criteria:
inclusion criteria: 1. any male or female patient aged 18 or older. 2. histologically confirmed bladder cancer, cystectomy was performed after nac. 3. complete clinical data. exclusion criteria: 1. patients with severe organic disease who can not tolerate chemotherapy or surgery 2. patients received previous treatment (chemotherapy, radiation, or molecular targeted therapy). 3. patients with distant metastasis or other cancer history.

Keywords: bladder cancer neoadjuvant chemotherapy immunohistochemical biomarkers
evaluation of the safety and efficacy of paraplatin in combination with taxol in patients of 70 years and older with ovary cancer f.i.g.o. stages iii-iv

Conditions: Ovarian Cancer

Summary: safety and efficacy of paraplatin in combination with taxol in patients of 70 years or older with epithelial ovary cancer f.i.g.o. stages iii and iv.

the main objective of this study is to evaluate the faisibility of chemotherapy with paraplatin in combination with taxol in patients of 70 years or older with epithelial ovary cancer f.i.g.o. stages iii and iv and to determine principal predictive factors of this feasibility.

Eligibility criteria:
inclusion criteria: * histological or cytological proven diagnosis of epithelial ovary cancer f.i.g.o stages iii or iv (when only cytological proven diagnosis is available: malignant cells and pelvis tumoral mass and increased ca-125 must be diagnosed simultaneously) * patient aged \> 70 years * neutrophil polynuclears \> 1500/mm3 and platelets \> 100 000/mm3 * no clinical icterus * life expectancy of at least 3 months exclusion criteria: * previous diagnosis of malignancy * previous chemotherapy treatment * previous radiotherapy * hypersensitivity to products containing cremophore el * hepatic values: bilirubine \> 2\*lsn, sgot-sgpt \> 2\*lsn and/or alkalin phosphatase \> 3\*lsn * myocardiopathy with arrhythmia

Keywords: epithelial ovary cancer f.i.g.o. stages iii or iv 70 years or older
music listenıng and training before coronary angıography

Conditions: Coronary Artery Disease; Anxiety; Music; Education

Summary: the aim of this study was to investigate the effects of education and music listening on the anxiety and physiological parameters experienced by individuals undergoing elective coronary angiography.

the aim of this study was to investigate the effects of education and music listening on the anxiety and physiological parameters experienced by individuals undergoing elective coronary angiography. the population of the study consisted of individuals undergoing elective coronary angiography in the cardiology department of abant i̇zzet baysal university i̇zzet baysal training and research hospital. the study was conducted in a randomized controlled manner with three groups: 34 individuals in music listening group (m1), 34 individuals in information training group (m2) and 34 subjects in control group. in order to collect data, cag (coronary angiography) procedure training form, patient identification form, physiological parameters form and visual analogue scale and spielberg state and trait anxiety scale were used. data were collected by face to face interview technique. descriptive statistics, independet simple test, paired sample t test, kruskall wallis, mann whitney u test and wilcoxon signed rank test were used in the analysis of the data and the significance level was accepted as p \<0.05.

Eligibility criteria:
inclusion criteria: applying femoral cag electively, * the first time cag will be held, * performing the cag procedure for diagnostic purposes, * not trained on the cag process, * volunteering to participate in the study, * no problem in verbal communication, * no hearing loss, * being able to read and write, * has not been diagnosed with psychiatric illness, * being conscious, * being 18 or older. exclusion criteria: radial application of cag, * previously performing coronary angiography, * performing the cag procedure for therapeutic purposes (stent, balloon, etc.), * having received training on the kag process, * does not want to participate in the study * problems in verbal communication, * hearing loss, * psychiatric illness is found. * consciousness is closed.

Keywords: coronary angiography teaching music theraphy anxiety nursing care
real world study in locally advanced or metastatic nsclc patients, progressed from first-line egfr-tki therapy

Conditions: Locally Advanced or Metastatic NSCLC

Summary: to estimate parameters associated with treatment patterns and related clinical outcomes.including physician reported pfs and os.

the objectives of this study are to assess molecular testing, treatment patterns, and associated clinical outcomes among patients with epidermal growth factor receptor (egfr) mutation-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have progressed from first-line egfr-tki (tyrosine kinase inhibitor) therapy. this study is descriptive in nature and does not attempt to test any specific a priori hypotheses

Eligibility criteria:
inclusion criteria 1. male or female patients with age ≥18 years old 2. histologically or cytologically confirmed locally advanced or metastatic nsclc patients 3. patients with prior confirmed egfr mutation-positive, who have progressed from first line egfr-tki\* 4. provision of written informed consent by the patient should be within 6 weeks of the date of progression from first line egfr-tki treatment \*note： 1. first-line egfr-tki is monotherapy; 2. egfr-tki has been launched in china includes first-generation, second-generation or third-generation egfr-tki, but not including the original chemical compound 3. exclude the chinese traditional medicine that is being used to treat lung cancer 4. progression was determined according to recist1.1 criteria. exclusion criteria 1. involvement in the planning and/or conduct of the other intervention study 2. previous enrolment in the present study 3. pregnancy or breast-feeding

Keywords: nsclc
ucb antiepileptic drugs (aed) pregnancy registry (formerly the keppra® pregnancy registry)

Conditions: Birth Defects; Pregnancy Complications; Epilepsy; Seizures

Summary: this is a prospective, observational, exposure-registration and follow-up study of women and their offspring exposed to keppra® (levetiracetam) and keppra xr® at the time of conception (i.e., any time from the first day of the last menstrual period) and/or during pregnancy. the ucb aed pregnancy registry is designed to monitor pregnancies exposed to keppra® and keppra xr® in order to determine if there is a potential increase in the risk of major birth defects compared to rates from women in the general us population. the objectives of the ucb aed pregnancy registry are: * to prospectively collect data concerning 1) exposure to keppra® and keppra xr® during pregnancy, 2) potential confounding factors, 3) outcome of pregnancy, and 4) long-term pediatric outcome * to review reported cases of possible birth defects * to estimate the risk of birth defects occurring in live-born offspring of women exposed to keppra® and keppra xr® during pregnancy this study is being conducted in the united states (us). enrollment in the registry is voluntary. the ucb aed pregnancy registry is sponsored by ucb, inc. and is managed by inc research. the scientific conduct and analysis of the registry is overseen by an expert panel consisting of external specialists in teratology/genetics, epidemiology, maternal and fetal medicine, and neurology (external member details available upon request).


Eligibility criteria:
inclusion criteria: the subjects must meet the following criteria for registration: * enroll prospectively (patient is still pregnant and no structural defects have been noted on a prenatal test) * exposure to keppra® and keppra xr® on or after the first day of the patient's last menstrual period (verified by date or gestational age of exposure) * for patient-initiated enrollments, provide verbal or written consent to participate in the registry * for patient-initiated enrollments, provide contact information for herself, her hcp, and the infant's hcp (as applicable)

Keywords: birth defects epilepsy high risk pregnancy
exercise in pregnancy and risk of postpartum depression

Conditions: Depression; Pregnancy Related

Summary: the prevalence of postpartum depression (ppd) varies between 11.9% and 19.2% during the perinatal period. ppd refers to minor and major depression incidents that occur during pregnancy or shortly after (up until 12 months after birth). the symptoms of ppd embrace feeling sad or having a depressed mood, being uninterested in the new-born, unreasonable crying and fear of injuring or harming the baby. consequently, ppd can negatively impact the mother's well-being and the baby's development. the impact on a child can be short for cognitive and motor development . although medication is a feasible alternative, many women have constraints due to continuing breastfeeding. therefore, exercise can be an alternative that could help to deal with ppd. exercise can be used as a preventive or treatment of mild depression at an early stage and as an addition to a treatment plan for major depressive disorder. exercising during pregnancy and postpartum improves psychological health and also benefits physical fitness, weight gain control and the prevention or reduction of musculoskeletal discomfort and pain. therefore, the american college of obstetrics and gynaecologists has recommended that women during pregnancy and postpartum engage in moderate-intensity physical activity almost every day for 30 min a day

the prevalence of postpartum depression (ppd) varies between 11.9% and 19.2% during the perinatal period. ppd refers to minor and major depression incidents that occur during pregnancy or shortly after (up until 12 months after birth). the symptoms of ppd embrace feeling sad or having a depressed mood, being uninterested in the new-born, unreasonable crying and fear of injuring or harming the baby. consequently, ppd can negatively impact the mother's well-being and the baby's development. the impact on a child can be short for cognitive and motor development . although medication is a feasible alternative, many women have constraints due to continuing breastfeeding. therefore, exercise can be an alternative that could help to deal with ppd. exercise can be used as a preventive or treatment of mild depression at an early stage and as an addition to a treatment plan for major depressive disorder. exercising during pregnancy and postpartum improves psychological health and also benefits physical fitness, weight gain control and the prevention or reduction of musculoskeletal discomfort and pain. therefore, the american college of obstetrics and gynaecologists has recommended that women during pregnancy and postpartum engage in moderate-intensity physical activity almost every day for 30 min a day

Eligibility criteria:
inclusion criteria: * singleton gestation * low risk pregnancy * age between 20 and 40 exclusion criteria: * high risk pregnancy * multiple gestation * prior post partum depression * any psychiatric disase * controindication for exercise * lung or heart disease * prior preterm birth * ivf pregnancy * women who already perform agonistic sport activity
multi-omics characteristics and prognosis of idiopathic sudden sensorineural hearing loss

Conditions: Sudden Sensorineural Hearing Loss; Hearing Loss, Sensorineural; Hearing Loss, Sudden

Summary: the goal of this observational study is to describe the multi-omics characteristics and to learn about the prognostic factors in patients with idiopathic sudden sensorineural hearing loss (ssnhl). the main problems it aims to deal with are: * if there is a difference in data of exome and targeted sequencing among patients with ssnhl affecting bilateral and unilateral sides, and healthy controls * if there is a difference in the parameter of mri among patients with ssnhl affecting bilateral and unilateral sides, and healthy controls * to find out which factor from multi-omics data relates to outcomes of ssnhl * to develop the best prognostics model based on the multi-omics data. participants will be received audiological tests, blood specimen collection and radiological examination. researchers will explore the relationship between the multi-omics data and the prognosis and develop the predictive model.


Eligibility criteria:
inclusion criteria: * age ≥ 4 * participants with ssnhl: unilateral or bilateral sensorineural hearing loss of \> 30 db hl (decibel) involving at least 3 continuous test frequencies developing within 72 hours * healthy controls: people with pta thresholds of all test frequencies ≤ 20 db hl and without otologic disease in the last 3 months * completed informed consent and promised to finish follow-ups exclusion criteria: * hearing loss with explicit causes, including noise-induced, ménière's disease, ototoxicity exposure, mumps infection or history of syphilis infection and so on. * a history of head trauma or otologic surgery. * malformation of temporal bone discovered by computed tomography (ct) * retro-cochlear lesion discovered by magnetic resonance imaging (mri) * pregnant women
incretin effect in people with impaired fasting glucose

Conditions: Obesity

Summary: regulation of endogenous glucose production (egp) and insulin secretion are major actions of glucagon-like peptide-1 (glp-1). determining whether alterations in glp-1 may contribute to abnormal egp and insulin secretion in people with impaired fasting glucose (ifg) was the objective of the current study. the investigators hypothesized that defects in glp-1 may explain the inappropriate basal egp and diminished insulin secretion in ifg, and, furthermore, that by increasing circulating glp-1 levels (using a new medicine called "sitagliptin") the investigators could reverse these defects.


Eligibility criteria:
inclusion criteria: * healthy, sedentary, non-smokers, men and women 45-70 years old subjects were placed into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h ogtt), separated by one week: a control group with normal glucose tolerance (ngt; n=14; fasting glucose \<5.6 mmol/l and 2h ogtt \<7.8 mmol/l), or ifg (n=10; fasting glucose 5.6-6.9 mmol/l, and 2h ogtt \<7.8 mmol/l). exclusion criteria: * subjects were excluded for: thyroid stimulating hormone \ 500 milliunits/l, fasting triglycerides \>10.3 mmol/l, creatinine \>130 μmol/l, elevated liver function tests (\>2 times normal), hematocrit \ 40 kg/m2. diabetes or impaired glucose tolerance.

Keywords: pre-diabetes isotopes insulin secretion insulin action glp-1 simple obesity impaired fasting glucose
an observational cohort study to describe and compare the use of darolutamide, enzalutamide and apalutamide and how well these work in men with non-metastatic castration-resistant prostate cancer (nmcrpc) in real world settings

Conditions: Non-metastatic Castration-resistant Prostate Cancer

Summary: this is an observational cohort study in men with non-metastatic castration-resistant prostate cancer who received their usual treatment, which is 'androgen receptor inhibitors' (aris) including darolutamide, enzalutamide, and apalutamide. the main purpose of this study is to collect data on the length of time men with nmcrpc continued treatment with darolutamide, enzalutamide, or apalutamide as prescribed by their doctors. researchers will only include men who had not been treated with any new type of medication that blocks the action of hormones. the data will come from an electronic health record database called precision point specialty (pps) prostate cancer electronic medical record (emr) for men in the united states of america. emr data will be verified and supplemented via patient chart review. data collected will be from january 2019 to september 2023. .


Eligibility criteria:
inclusion criteria: 1. men diagnosed with prostate cancer. 2. diagnosis of nmcrpc prior to or within 90 days after the first ari treatment initiation 3. treatment with darolutamide, enzalutamide, or apalutamide initiated for the first time 4. age ≥ 18 years at treatment start 5. at least 6 months of electro-medical-record activity after the treatment start unless the patient died earlier than 6 months. exclusion criteria: 1. evidence of metastatic disease before or 30 days after treatment start 2. prior history of other primary cancers
efficacy and safety of once daily dosing of aliskiren (300 mg (qd) once a day) to twice daily dosing of aliskiren (150 mg (bid) twice a day) in treating moderate hypertension.

Conditions: Essential Hypertension

Summary: this study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension


Eligibility criteria:
inclusion criteria: * have diagnosis of uncomplicated essential hypertension; newly diagnosed or who have not received antihypertension medication within 4 weeks of visit 1 must have an office cuff mean sitting diastolic blood pressure (msdbp) \> 100 mmhg and \ 95 mmhg and \< 110 mmhg at visit 1 * prior to randomization, all patients must have an office cuff msdbp \>or= 100 mmhg and \<or = 110 mmhg. exclusion criteria: * participation in another aliskiren trial or previous treatment with aliskiren during last 6 months and who qualified to be randomized or enrolled into the active drug treatment period * pregnant or nursing women * women of child bearing potential unwilling to use protocol specific contraceptive methods * office cuff blood pressure of msdbp ≥ 112 mmhg and/or mean sitting systolic blood pressure (mssbp) ≥ 200 mmhg). * secondary form of hypertension * history of heart failure new york heart association (nyha class ii, iii and iv) * previous history of hypertensive encephalopathy or stroke, transient ischemic attack (tia), heart attack, coronary bypass surgery or any percutaneous coronary intervention (pci) * elevated serum potassium (\> or = 5.3 meq/l (mmol/l) at visit 1 * type 1 or type 2 diabetes mellitus not well controlled * other protocol-defined inclusion/exclusion criteria may apply

Keywords: essential hypertension
ethanol sclerotherapy prior to art

Conditions: Endometrioma; Infertility; Sclerotherapy; ART; IVF

Summary: the goal of this randomized controlled trial is to assess the impact of ethanol sclerotherapy on art cycle outcomes. the main questions it aims to answer are: 1. does ethanol sclerotherapy before art cycle has any impact on cumulative live birth rate in patients with endometrioma? 2. does ethanol sclerotherapy improve chronic pelvic pain, dysmenorrhea, complications during oocyte retrieval, response to ovarian stimulation (number of mature oocytes retrieved), and pregnancy loss rates? infertile patients with endometrioma between 4-10 cm who are scheduled for art within 2 cycles will be randomized to ethanol sclerotherapy or no intervention.

the effect of ethanol sclerotherapy before assisted reproductive technology (art) cycle in patients with endometrioma on reproductive outcomes will be investigated. while endometrioma may result in technical difficulties in the art process, the superiority of ethanol sclerotherapy has yet to be examined before the art procedure in randomized controlled studies and meta-analyses. the negative effect of ethanol sclerotherapy on ovarian reserve was found to be less than other existing interventions such as cyst stripping. however, randomized controlled studies did not determine its direct effect on art outcome. our current study aimed to assess the effect of ethanol sclerotherapy on art outcomes. infertile patients aged 18-40 years with at least one endometrioma 4-10 cm and scheduled for art will be included in the study. patients with any untreated thyroid dysfunction or additional disease, such as hyperprolactinemia, those who did not accept the study information and consent, and patients younger than 18 or older than 40 will not be included. those who underwent surgery for endometrioma within 3 months before art will be excluded. in addition, patients with an anti-mullerian hormone value below 0.3 ng/ml will not be included in the study.

Eligibility criteria:
inclusion criteria: * amh\>0.3 ng/ml * unilateral/bilateral endometrioma * endometrioma diameter 40-100 mm exclusion criteria: * 3 or more ivf/embryo transfer failure * menstrual cycle abnormalities * male factor infertility * presence of uterine fibroids * presence of hydrosalpinx * presence of uterine abnormalities * suspicion of malignancy according to international ovarian tumor analysis criteria

Keywords: endometrioma ethanol sclerotherapy assisted reproductive technology in vitro fertilization cumulative live birth rate